Contrave, a combination of naltrexone and bupropion, has been approved by the FDA for chronic weight management.
- TRADE NAMES: Wellbutrin (GSK); Zyban (GSK)
- INDICATIONS:
Depression, aid to smoking cessation.
Adjunct for the treatment of obesity and for weight loss management in defined populations and health conditions.
- CLASS: Anti-obesity / weight loss pharmacotherapy, Antidepressant, Dopamine reuptake inhibitor
- HALF-LIFE: 14 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amitriptyline, Citalopram, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Cyclosporine, Deutetrabenazine, Efavirenz, Eluxadoline, Erythromycin, Escitalopram, Isocarboxazid, Levodopa, Linezolid, Lopinavir, Lorcaserin, Methylphenidate, Mifepristone, Oliceridine, Phenelzine, Ritonavir, Tranylcypromine, Trimipramine, Vortioxetine
- See adverse reactions attributed to class:
NEUROPSYCHIATRIC REACTIONS; AND SUICIDAL THOUGHTS AND BEHAVIORS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of naltrexone/bupropion in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/28/2025
